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p53 is a well-known tumor suppressor that has emerged as an important player in energy
balance. However, its metabolic role in the hypothalamus remains unknown. Herein, we show
that mice lacking p53 in agouti-related peptide (AgRP), but not proopiomelanocortin
(POMC) or steroidogenic factor-1 (SF1) neurons, are more prone to develop diet-induced
obesity and show reduced brown adipose tissue (BAT) thermogenic activity. AgRP-specific
ablation of p53 resulted in increased hypothalamic c-Jun N-terminal kinase (JNK) activity
before the mice developed obesity, and central inhibition of JNK reversed the obese phe-
notype of these mice. The overexpression of p53 in the ARC or specifically in AgRP neurons
of obese mice decreased body weight and stimulated BAT thermogenesis, resulting in body
weight loss. Finally, p53 in AgRP neurons regulates the ghrelin-induced food intake and body
weight. Overall, our findings provide evidence that p53 in AgRP neurons is required for
normal adaptations against diet-induced obesity.
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The arcuate nucleus of the hypothalamus (ARC) is criticalfor the regulation of energy balance since it receives directsignals (hormones and nutrients) from the periphery1 and
comprise two neuronal populations that modulate food intake,
energy expenditure, and nutrient partitioning2. Neurons leading
to a positive energy balance express agouti-related protein (AgRP)
and neuropeptide Y (NPY), while neurons leading to a negative
energy balance express proopiomelanocortin (POMC)3–5.
Data gleaned in recent years have allowed uncovering of sev-
eral mechanisms implicated in obesity development and main-
tenance. Interestingly, many of these mechanisms have been
shown to act in the hypothalamus, via altering of intercellular
communication by signals such as hormones/adipokines, dysre-
gulated nutrient sensing, and alteration in stress and inflamma-
tory responses2,6. Accumulating evidence indicates that these
peripheral signals act via specific hypothalamic nutrient and/or
energy sensors, with deletion or activation in specific hypotha-
lamic areas of sirtuin 1, AMP-activated protein kinase, mam-
malian target of rapamycin, and liver kinase B1 demonstrated to
modulate whole-body energy balance7–11. Of note, it has recently
been postulated that some of these signals/nutrient sensors may
exert their effects by influencing hypothalamic proteostasis6.
p53 is a tumor suppressor activated in response to various
stimuli12–15 and is also considered as a metabolic sensor16.
Cumulative evidence has placed this protein, beyond its role in
cancer, as a relevant metabolic regulator through its actions on
glycolysis, oxidative phosphorylation, amino acid and lipid
metabolism12,15,17. Reports showing that some p53 mutations are
related with metabolic alterations suggest the clinical relevance of
p53 in this regard. Patients with the Li Fraumeni syndrome,
which is an autosomal dominant cancer predisposition disorder
caused by some p53 mutations, have increased oxidative phos-
phorylation of skeletal muscle18. Moreover, the so-called
p53 signature, an indicator of higher ovarian cancer risk in
women with BRCA mutations, was inversely associated with body
mass index19. In line with this, preclinical studies manipulating
p53 in peripheral tissues showed important effects in the whole-
body metabolism with pathological implications for obesity and
type 2 diabetes15,20–26. In the hypothalamus, acetylated levels of
p53 are decreased after fasting27 and recovered after refeeding28.
However, the pathological implications as well as the potential
metabolic role of p53 in the hypothalamus remain completely
unknown.
Here, we provide compelling evidence that hypothalamic p53 is
a key factor in the regulation of energy balance. These metabolic
actions rely specifically on AgRP neurons, since mice lacking p53
in AgRP neurons (AgRPp53 KO) are more susceptible to gain
weight when fed a high fat diet (HFD), which is not the case when
p53 is lacking in ARC POMC or SF1 neurons in the ventromedial
nucleus of the hypothalamus (VMH). In agreement with this,
mice with genetic overexpression of p53 in the ARC and more
precisely in AgRP neurons are protected against diet-induced
obesity (DIO). The mechanism underlying p53 actions on energy
balance involves JNK1. Finally, AgRPp53 KO mice do not
respond to the most potent peripheral orexigenic signal, namely,
ghrelin.
Results
Genetic inhibition of p53 in the ARC increases weight gain. To
analyze the role of p53 in the regulation of energy balance at the
central level, we started with a virogenetic approach to inhibit p53
in two different hypothalamic nuclei involved in the control of
energy homeostasis, namely, ARC and VMH. For this, we
injected Ad-GFP alone or a mutant Tp53RK, which acts as a
dominant negative (Ad-DNp53RK) to inhibit p53 activity and
function24 in rats fed a chow diet. The efficacy of the stereotaxic
injections in the ARC was corroborated by immunostaining of
GFP and DAPI (Fig. 1a) with 20% of the cells transduced after the
viral injection (Supplementary Fig. 1). The functional efficiency of
the viral vectors was demonstrated by decreased protein levels of
phopho-p53 (active form of p53) in the ARC (Fig. 1b)24. The
inhibition of p53 activity in the ARC increased body weight
(Fig. 1c), food intake (Fig. 1d), and adiposity (Fig. 1e) after 9 days.
This phenotype was associated with decreased temperature in the
interscapular BAT (Fig. 1f), increased size of BAT lipid droplets
(Fig. 1g), and the reduced protein levels of BAT uncoupling
protein 1 (UCP1) (Fig. 1h). BAT is connected with the CNS via
the sympathetic nervous system (SNS), which modulates BAT
activity through the β-adrenergic receptors. We found lower
mRNA expression of β-adrenergic receptors in BAT of Ad-
DNp53RK rats (Fig. 1i), suggesting that inhibition of p53 in the
ARC decreases SNS signaling. In addition, inhibition of p53
activity in the ARC resulted in bigger white adipocytes compared
with the control group (Fig. 1j) and increased peroxisome
proliferator-activated receptor gamma (PPARg) gene expression
in WAT (Fig. 1k), suggesting that the inhibition of p53 activity in
the ARC promotes adipogenesis.
The role of p53 in the ARC appears to be nucleus-specific,
since no effect on body weight or food intake was detected when
the same viral vector targeted the VMH (Supplementary
Fig. 2a–c) or in mice lacking p53 in SF1 neurons (SF1p53 KO)
fed either chow diet or HFD (Supplementary Fig. 2f–r).
p53 is upregulated in the hypothalamus of diet-induced
obese mice. p53 levels are higher in the white adipose tissue21
and in the liver29 of obese mice. Herein, we found a significant
increase in p53 protein levels in the ARC of DIO rats and in the
mediobasal hypothalamus of DIO mice (Supplementary Fig. 3a,
b). Consistent with this, HFD activated the p53 signaling pathway
since it stimulated protein levels of the p53 downstream mole-
cules p66-Shc and Bax in the mediobasal hypothalamus of DIO
mice (Supplementary Fig. 3c). When p53 protein levels were
measured in the mediobasal hypothalamus of mice fed a HFD
during 2 and 4 weeks, before developing obesity, we did not find
differences in p53 levels in comparison to mice fed a chow diet
(Supplementary Fig. 3d, e).
Ablation of p53 in AgRP increases susceptibility to DIO. To
shed more light about which neuronal population within the ARC
is required for the metabolic actions of p53, we generated mice
with selective ablation of p53 in POMC or AgRP neurons, using
specific Cre transgenic mouse lines. To confirm whether mutant
mice lack p53 in AgRP or POMC neurons, the tdTomato-reporter
allele was introduced to allow expression of the fluorescent pro-
tein tomato in these neurons, as previously described30. Double
immunohistochemistry revealed that p53 and tdTomato were
colocalized in the ARC of control mice, and we detected p53 in
approximately 80% of AgRP and POMC, while the colocalization
observed in POMC-Cre or AgRP-Cre p53loxP/loxP mice was much
lower (Supplementary Fig. 4b, c), verifying p53 deletion in
hypothalamic in POMC or AgRP neurons, respectively. More-
over, FACS sorting and single-cell RNA sequencing of AgRP-
eGFP neurons showed that 31 out of 45 (69%) AgRP neurons
express p53 (GEO Database repository: GEO Accession:
GSE92707) (Supplementary Fig. 4a).
POMCp53 KO mice showed no differences in food intake,
body weight, body composition, glucose tolerance, or insulin
sensitivity when compared with their control littermates after
18 weeks on chow diet or HFD (Fig. 2a–m). Similarly, AgRPp53
KO mice fed a chow diet did not show differences in body weight,
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food intake (Fig. 3a, b). However, when fed a HFD, a significant
increase in body weight, food intake, and adiposity was found
among male AgRPp53 KO mice compared with wild type (WT)
controls (Fig. 3a–d and Supplementary Fig. 5). AgRPp53 KO
mice exhibited reduced locomotor activity and energy expendi-
ture, without changes in respiratory quotient (Fig. 3e–h) or body
length (Supplementary Fig. 5). In agreement with decreased
energy expenditure, AgRPp53 KO mice fed a HFD had a lower
interscapular surface temperature adjacent to BAT (Fig. 3i), more
lipid droplets in the BAT (Fig. 3j), and downregulated protein
levels of BAT UCP1 (Fig. 3k). In keeping to the increased
adiposity, histomorphological analysis revealed significantly
larger white adipocytes (Fig. 3l) and increased lipid content in
the liver (Fig. 3m) in AgRPp53 KO mice following HFD exposure,
but these mice did not exhibit differences in glucose tolerance or
insulin sensitivity (Fig. 3n, o). Mice with genetic ablation of p53
in AgRP neurons showed a significant increase in food intake
during the last weeks of HFD, much later than changes in body
weight were detected, suggesting that the higher susceptibility to
DIO occurs in a feeding-independent manner. Since AgRP
neurons play a key role in the regulation of food intake, we next
investigated whether p53 in AgRP neurons might be involved in
the fasting-induced hyperphagia. Thus, mice were fasted over-
night and then refed for 4 h. Mice lacking p53 in AgRP neurons
showed a non-significant trend toward decreased fasted-induced
hyperphagia (Supplementary Fig. 6a). Alteration of circadian
pattern of feeding has been associated with obesity31 and p53 has
been reported to interact with the circadian clock32. Therefore, we
next assessed whether mice lacking p53 in AgRP fed a HFD for
10 weeks, when body weight was already increased compared to
their littermates, but we failed to detect any change in food intake
along the circadian cycle (Supplementary Fig. 6b, c).
Given the potentially pleotropic effects of p53 not only on cell
activity but also on multiple biological actions, we measured
AgRP fiber density in the ARC and paraventricular nucleus
(PVH) of mice fed a HFD for 13 weeks and found that the
number of fibers were identical between both genotypes
(Supplementary Fig. 7). This indicates that the lack of p53 is
not damaging these neurons at least not at this time point. In
addition, we have also quantified the number of AgRP neurons
and total number of cells in WT and conditional KOs and found
that they were very similar between genotypes (Supplementary
Fig. 8). Given the role of p53 in stress response and that
hypothalamic inflammation influences energy balance33, we
performed immunostaining of GFAP and Iba1 in the hypotha-
lamic ARC of mice and also measured protein levels of some
inflammatory markers (IL-6 and IL-1β) in the mediobasal
hypothalamus of WT and mice lacking p53 in AgRP neurons
p-p53
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Fig. 1 Effects of virogenetic inhibition of p53 into the ARC of rats fed chow diet on energy balance. Representative immunofluorescence showing GFP and
DAPI expression in the ARC (a). ARC protein levels of phospho-p53 and p53 (b). Body weight change (c); cumulative food intake (d); fat mass
(e); representative infrared thermal images and temperature of the BAT (f); representative pictures of BAT histology (g); BAT protein levels of UCP1
(h); BAT mRNA expression of UCP3, β1-adrenergic, β2-adrenergic, and β3-adrenergic receptors (i); representative pictures of WAT histology (j); and WAT
mRNA expression of PPARγ, β1-adrenergic, β2-adrenergic, and β3-adrenergic receptors and CEBPα (k) of rats after 9 days of the injection of Ad-GFP and
Ad-DNp53RK in the ARC. β-actin and α-tubulin were used to normalize protein levels. Dividing lines indicate spliced bands from the same gel. Values are
mean ± SEM of 6–8 animals per group. *P < 0.05; **P < 0.01
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05711-6 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:3432 | DOI: 10.1038/s41467-018-05711-6 |www.nature.com/naturecommunications 3
after 13 weeks of HFD and no differences were found
(Supplementary Fig. 9a–g). We also measured markers of
apoptosis (caspase 3 and 7) and senescence (Poly (ADP-ribose)
polymerase 1, PARP1) in control and AgRPp53 KO mice fed a
HFD for 13 weeks. However, we did not find any change in these
markers (Supplementary Fig. 9h).
Ablation of p53 does not change AgRP neuron activity. Next,
we assessed the effect of AgRP neuron-specific ablation of p53 on
the intrinsic electrophysiological properties of these neurons
during DIO. To this end we performed perforated patch clamp
recordings in brain slices of AgRP-Cre and AgRPp53 KO mice
fed a HFD for 10 weeks and injected with AAV-DIO-hSyn-EGFP
in the mediobasal hypothalamus. Both mouse lines showed a
pattern of GFP label in the ARC, which is consistent with pre-
viously described AgRP expression pattern in the ARC. For post
hoc identification, cells were loaded with biocytin by converting
the perforated patch configuration to the whole-cell configuration
at the end of the recording. The identity of AgRP neurons was
then confirmed by double-labeling of the recorded neuron with
GFP immunoreactivity and biocytin (Fig. 4). During the
recording GABAergic and glutamatergic synaptic input was
pharmacologically blocked to minimize influence from the net-
work. Assessing several key electrophysiological parameters such
as spontaneous firing rate, input resistance, spike frequency
adaptation (SFA), spike threshold, and excitability did not reveal
differences between the AgRP neurons in the two mouse lines
(Fig. 4).
UPR function reverses the phenotype of AgRPp53 ko mice.
Recent data demonstrate that hypothalamic activation of the
unfolded protein response (UPR) plays a primary pathogenic role
in obesity. Diet-induced and genetic models of obesity have been
associated with activated hypothalamic UPR34–40. We therefore
evaluated the protein levels of UPR markers in our animal
models. First, we found that rats injected with a mutant Tp53RK
in the ARC showed diminished protein levels of BIP/GRP78, a
chaperone that facilitates the proper protein folding acting
upstream of the UPR41, and increased protein levels of each UPR
marker analyzed, Inositol requiring enzyme 1 (IRE1), activating
transcription factor 6 alpha (ATF6α), and CCAAT/enhancer-
binding protein-homologous protein (CHOP) (Fig. 5a). We also
found increased protein levels of phosphorylated-SAPK/JNK
(Thr183/Tyr185) (pJNK) and its upstream kinases42, MKK4 and
MKK7 in the mediobasal hypothalamus of AgRPp53 KO mice fed
a HFD for 13 weeks (Fig. 5b). We next evaluated the protein
levels of UPR markers in the mediobasal hypothalamus of
AgRPp53 KO mice fed a HFD for 13 weeks, and similarly found
decreased GRP78 and increased the levels of IRE1, pPERK, and
ATF6α (Fig. 5b).
Our results indicate that the loss of p53 in the ARC is
associated with increased ER stress, and we next aimed to
determine the relevance of UPR as a mediator of the central
actions of p53. For this purpose, we relieved ER stress using
tauroursodeoxycholic acid (TUDCA), a chemical chaperone
known to improve ER function and decrease the accretion of
misfolded proteins in the ER lumen43. AgRPp53 KO and control
littermates fed a HFD were treated intracerebroventricular (i.c.v.)
with vehicle or TUDCA (5 µg/mouse/day) during 7 days.
TUDCA administration did not modify food intake or body
weight gain in WT mice (Fig. 5c, d). However, the central
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Fig. 2 Ablation of p53 in POMC neurons does not alter energy balance. Food intake (a); body weight (b); glucose tolerance test (c); and insulin tolerance
test (d) in control and POMCp53 KO mice fed a chow diet. Food intake (e); body weight (f); glucose tolerance test (g); insulin tolerance test (h); fat mass
(i); lean mass (j); energy expenditure (EE) (k); locomotor activity (l); and respiratory quotient (RQ) (m) in control and POMCp53 KO mice fed a HFD.
Values are mean ± SEM of 9–22 animals per group. *P < 0.05
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weight-reducing effect in AgRPp53 KO mice compared to
vehicle-treated mice (Fig. 5c, e). Consistent with these results,
adiposity was normalized in AgRPp53 KO mice treated with
TUDCA, the size of white adipocytes and lipid droplets in BAT
was reduced, and BAT UCP1 protein levels were elevated
(Fig. 5f–i).
JNK mediates the effects of AgRP p53 on energy balance. Since
we found that the inhibition of p53 activity in the ARC and the
lack of p53 in AgRP neurons enhanced MKK4, MKK7, pJNK, and
the levels of ER stress markers, we next assessed whether the
upregulation of those factors could be observed before AgRPp53
KO mice develop obesity. We fed control and AgRPp53 KO mice
a HFD for 3 weeks and then measured protein levels of MKK4,
MKK7, pJNK, and ER stress markers in the mediobasal hypo-
thalamus. At this time point there was a tendency of increased
food intake, but there were no differences in body weight, energy
expenditure, locomotor activity, respiratory quotient, lipid dro-
plets in the BAT or BAT UCP1 levels between the two genotypes
(Fig. 6a–i), whereas the protein levels of MKK7 and phosphory-
lated levels of JNK were already increased, while the levels of ER
stress markers remained unchanged (Fig. 6j). Thus, these results
suggest that the upregulation of MKK7 and further activation of
JNK precedes changes in hypothalamic ER stress and obesity in
AgRPp53 KO mice fed a HFD.
Given these results, we hypothesized that JNK may play a key
role in the development of obesity caused by the lack of p53 in
AgRP neurons. To test this, AgRPp53 KO and control littermates
fed a HFD were treated i.c.v. with vehicle or the JNK inhibitor SP-
600125 (1.5 µg/mouse/day) during 6 days44. The administration
of SP-600125 did not modify food intake or body weight gain in
control mice (Fig. 7a–c). However, in AgRPp53 KO mice, central
administration of SP-600125 decreased body weight and tended
to inhibit food intake compared to vehicle (Fig. 7a–c). Con-
sistently, AgRPp53 KO mice treated with SP-600125 showed
reduced adiposity and white adipocyte size, while interscapular
temperature was increased, BAT UCP-1 protein levels were
stimulated and lipid droplets in BAT were reduced (Fig. 7d–i).
Collectively, the data indicate that the central inhibition of JNK
reverses the obese phenotype of AgRPp53 KO mice fed a HFD.
Importantly, the dose of SP-600125 used did not modify body
weight, food intake, or adiposity in WT mice fed a chow diet
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Fig. 3 Ablation of p53 in AgRP neurons is associated with a positive energy balance during long-term HFD. Body weight (a) and food intake (b) of control
and AgRPp53 KO mice fed a chow diet and HFD for 13 weeks. Fat mass (c); non-fat mass (d); locomotor activity (LA) (e); respiratory quotient (RQ)
(f); energy expenditure (g–h); representative infrared thermal images and temperature of the BAT area (i); representative BAT histology pictures
(hematoxylin-eosin) (j); BAT protein levels of UCP1 (k); representative WAT histology pictures (hematoxylin-eosin) (l); representative liver histology
pictures (hematoxylin-eosin, upper and oil-red O staining, lower) (m); glucose tolerance test (n); and insulin tolerance test (o) of control and AgRPp53 KO
mice fed a HFD. α-tubulin was used to normalize protein levels. Dividing lines indicate spliced bands from the same gel. Values are mean ± SEM of 5–15
animals per group. *P < 0.05; **P < 0.01
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SP-600125 increased protein levels of IL-1β and caspase 3 in the
mediobasal hypothalamus (Supplementary Fig. 10f–g), the JNK
inhibitor did not negatively affect AgRP fiber density in the ARC
and PVH (Supplementary Fig. 11), indicating that this compound
is not damaging these neurons.
To further analyze the role of JNK as a mediator of the effects
of hypothalamic p53, we next inactivated hypothalamic p53 in
WT and JNK1 KO mice fed a chow diet. The inhibition of p53 in
the ARC of WT mice induced weight gain, food intake, and
adiposity (Fig. 7j–m), reduced interscapular temperature (Fig. 7n),
increased lipid droplets in BAT (Fig. 7o), decreased BAT UCP1
protein levels (Fig. 7p, q), and increased the size of white
adipocytes (Fig. 7r). However, all these effects were totally blunted
in JNK1-deficient mice (Fig. 7j–r). Altogether, these results
indicate that hypothalamic p53 requires JNK1 to exert its actions
on energy homeostasis. Since the hypothalamic–pituitary–thyroid
axis has been reported to be involved in the metabolic regulation
by JNK45, we measured serum concentration of T4 in WT and
mice lacking p53 in AgRP neurons fed a HFD for 13 weeks. T4
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Fig. 12), suggesting that changes in thyroid status do not explain
the phenotype of these mice.
Activation of p53 in the ARC ameliorates DIO. Since the
inhibition of p53 in AgRP neurons induces weight gain and
decreases BAT thermogenic activity, we hypothesized that the
specific overexpression of p53 in the ARC of WT DIO mice might
be sufficient to increase the BAT thermogenic activity and to
ameliorate weight gain. For this, we injected adenoviruses
encoding either Ad-GFP or Ad-p53+ together with GFP into the
ARC. The efficacy of the stereotaxic injections in the ARC was













































Control + icv saline
AgRPp53 KO + icv saline
AgRPp53 KO + icv TUDCA (5 μg/mouse)
Control + icv TUDCA (5 μg/mouse)
0 60 120 180
ARC protein levels (arbitrary units)
MBH protein levels (arbitrary units)
240 300























100 μm 100 μm 100 μm 100 μm
100 μm 100 μm 100 μm 100 μm 100 μm 100 μm 100 μm 100 μm
BAT


































































































































Fig. 5 Improvement of ER function reverses the obese phenotype of AgRPp53 KO mice. Protein levels of GRP78, IRE1, ATF6α, CHOP, pJNK, and JNK in the
ARC of rats after 9 days of the injection of Ad-GFP and Ad-DNp53RK (a). Protein levels of GRP78, IRE1, pPERK, ATF6α, MKK4, MKK7, pJNK, and JNK in
the mediobasal hypothalamus of control and AgRPp53 KO mice fed a HFD for 13 weeks (b). Effects of 7 days i.c.v. injections of TUDCA (5 µg/mouse) or
vehicle to control and AgRPp53 KO mice fed a HFD on body weight change (c); cumulative food intake (d); mean daily energy intake (e); adiposity
(f); representative WAT histology pictures (hematoxylin-eosin) (g); representative BAT histology pictures (hematoxylin-eosin) (h); and immunostaining of
UCP1 in BAT (i). β-actin was used to normalize protein levels. Dividing lines indicate spliced bands from the same gel. Values are mean ± SEM of 5–10
animals per group. *P < 0.05; **P < 0.01; ***P < 0.001
Fig. 4 Cell type-specific ablation of p53 does not change AgRP neurons’ electrophysiological properties in DIO. Electrophysiological parameters of AgRP
neurons that were recorded in AgRP-Cre mice (black) and AgRPp53 KO mice (green) and a HFD for 10 weeks and injected in the mediobasal
hypothalamus with AAV-DIO-hSyn-EGFP that expressed GFP specifically in AgRP neurons. a Spontaneous activity. Original recordings (left) and mean
frequencies (right). b Mean input resistance. c Immunohistochemical identification of a recorded AgRP neuron expressing GFP (green) that was loaded
with biocytin (red) during the electrophysiological recording in the ARC. Excitabilty. d Representative voltage responses to increasing depolarizing current
injections (from 10 to 20 pA in 5 pA steps) elicited from a holding potential of −70mV. e Top: Mean spike count during the current pulses as a function of
injected current. Bottom: Mean increase in firing in response to the injected current (pA−1). f Spike frequency adaptation. Left: Original recording and
corresponding plots of the instantaneous spike frequency. Right: Mean SFA ratio and mean time constant of decay in instantaneous frequency. Analysis
was performed from traces with similar instantaneous frequency (30–35 Hz). g Current ramps were used to measure the spike threshold and voltage-
dependent sustained changes in activity. Left: Original recording. Right: (top) Mean threshold current to elicit action potentials; (bottom) ratio of spike
count between on and off ramp. Data are represented as mean ± SEM. N-values and p-values (unpaired Student’s t-test) are given above the bar graphs
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functional efficiency of the viral vectors was demonstrated by
increased protein levels of phosphorylated p53 in the ARC
(Fig. 8b). The p53 overexpression in the ARC of DIO mice sig-
nificantly decreased body weight and food intake (Fig. 8c, d). This
was associated with decreased adiposity without changes in non-
fat mass, increased energy expenditure, unchanged locomotor
activity, and decreased respiratory quotient (Fig. 8e–i). The
overexpression of p53 in the ARC of DIO mice increased inter-
scapular surface temperature in the BAT area (Fig. 8j), reduced
the lipid droplet size in BAT (Fig. 8k), and stimulated the
expression of BAT UCP1 (Fig. 8l). Accordingly, the size of white
adipocytes and the hepatic lipid content was reduced (Fig. 8m, n).
At the hypothalamic level, p53 overexpression in the ARC atte-
nuated DIO-induced ER stress, as indicated by the lower protein
levels of IRE, pPERK, CHOP, as well as MKK4, MKK7, and pJNK
(Fig. 8o). The overexpression of p53 also decreased protein levels
of caspase 7, without affecting caspase 3 or PARP in the med-
iobasal hypothalamus (Supplementary Fig. 13). To investigate the
effects of the overexpression of p53 when diet is modulated, we
overexpressed p53 in mice fed a chow diet. Under these condi-
tions, we did not find any change in body weight or other
metabolic parameters measured like food intake, body composi-
tion, BAT thermogenesis, or adipocyte size (Supplementary
Fig. 14). These new results reinforce the hypothesis that the
effects of hypothalamic p53 on body weight and metabolism
occur only in a HFD setting.
To further explore the role of p53 in AgRP neurons, we next
performed an experiment where we recovered the expression of
p53 specifically in AgRP neurons of AgRPp53 KO mice fed a
HFD injecting AAV-hSyn-DIO-p53. As expected, AgRPp53 KO
mice gained more weight than their controls when put under a
HFD (mice were fed a HFD for 10 weeks before the viral
injections), but when these mice were injected with the AAV-
hSyn-DIO-p53, they lost weight after 4 weeks in a food intake-
independent manner (Fig. 9a–c), which was consistent with a
reduction in fat mass, decreased adipocyte size, increase in BAT
temperature, and higher BAT UCP1 immunostaining (Fig. 9d–i).
Therefore, these results suggest that p53 specifically over-
expressed in AgRP neurons is sufficient to produce a catabolic
action in obese mice.
In addition to those genetic approaches, we assessed whether
central pharmacological stimulation of p53 would mimic the
findings obtained after genetic overexpression. First, we treated
rats with i.c.v. adriamycin (a drug activating p53) using osmotic
minipumps delivering 1 µg/rat/day for 5 days and found a
significant decrease in food intake and weight gain (Supplemen-
tary Fig. 15a, b). The control of BAT thermogenesis is regulated
by the SNS via the β-adrenergic receptors. To test if the effects of
20
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Fig. 6 Hypothalamic protein levels of MKK7 and pJNK are increased in AgRPp53 KO mice fed a HFD before displaying obesity. Food intake (a) and body
weight (b) of control and AgRPp53 KO mice fed a HFD for 3 weeks. Locomotor activity (LA) (c); respiratory quotient (RQ) (d); energy expenditure
(e); representative infrared thermal images and temperature of the BAT area (f); immunostaining and protein levels of UCP1 in BAT (g–h); representative
BAT histology pictures (hematoxylin-eosin) (i); protein levels of GRP78, XBP1, pPERK, CHOP, MKK4, MKK7, pJNK, and JNK in the mediobasal
hypothalamus of control and AgRPp53 KO mice fed a HFD for 3 weeks (j). β-actin and α-tubulin were used to normalize protein levels. Dividing lines
indicate spliced bands from the same gel. Values are mean ± SEM of 4–9 animals per group. *P < 0.05; **P < 0.01; ***P < 0.001
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hypothalamic p53 on BAT thermogenesis were driven by the
SNS, we treated rats with a β3 receptor antagonist (SR59230A)
together with i.c.v. adriamycin. We found that the reduction in
weight gain in animals treated with i.c.v. adriamycin was blocked
when the selective β3 receptor antagonist was subcutaneously co-
administered (Supplementary Fig. 15b) at a dose that does not
affect body weight per se46. Since the inhibition of p53 in the
ARC altered energy homeostasis, we next performed an
experiment infusing adriamycin directly in the ARC of rats using
osmotic minipumps (Supplementary Fig. 15c). Body weight and
fat mass were reduced independently of changes in food intake or
lean mass (Supplementary Fig. 15d–g), protein levels of pJNK in
the ARC were downregulated, BAT lipid droplets were reduced,
and BAT UCP1 protein levels were stimulated (Supplementary
Fig. 15h–j) in ARC adriamycin-treated animals in comparison to
vehicle rats.
p53 in AgRP neurons is essential for ghrelin. Given the critical
role played by p53 in AgRP neurons, we decided to investigate
whether it could also be involved in the signaling pathway
mediating the central effect of ghrelin47,48. We have previously
shown that central p53 plays an important role mediating
ghrelin-induced food intake28. Taking into account that the main
neuronal population targeted by ghrelin is AgRP49,50, we tested
the ability of central ghrelin to induce food intake in AgRPp53
KO mice. A single i.c.v. injection of ghrelin induced food intake
and body weight in control mice but not in AgRPp53 KO
(Fig. 10a, b). In agreement with this, AgRP and NPY mRNA
expression was increased in control mice, while this effect was not
found in AgRPp53 KO mice (Fig. 10c). The larger size of white
adipocytes found in control mice treated with ghrelin was not
detected in AgRPp53 KO-treated mice (Fig. 10d). Finally, the
ghrelin-induced expression of fatty acid synthase (FAS), acetyl
CoA carboxylase (ACC), and lipoprotein lipase (LPL) in control
mice (Fig. 10e) was not detected in AgRPp53 KO mice treated
with ghrelin (Fig. 10f). Finally, we also found higher levels of acyl-
ghrelin in AgRPp53 KO compared to control mice (Fig. 10g),
suggesting an overcompensating ghrelin resistance. Collectively,
our data indicate that p53 located in AgRP neurons is a key
modulator of ghrelin-induced feeding and adiposity.
Control + icv vehicle
Control + icv SP-600125 (1.5 μg/mouse)
AgRPp53 KO + icv vehicle
AgRPp53 KO + icv SP-600125 (1.5 μg/mouse)
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Fig. 7 Inhibition of central JNK reverses the obese phenotype of AgRPp53 KO mice. Body weight change (a); cumulative food intake (b); mean daily energy
intake (c); fat mass (d); representative infrared thermal images and temperature of the BAT area (e); BAT protein levels of UCP1 in control mice (f) and
AgRPp53 KO mice (g); representative WAT histology pictures (hematoxylin-eosin) (h); and representative BAT histology pictures (hematoxylin-eosin)
(i) after i.c.v. injections of SP-600125 (1.5 µg/mouse) or vehicle in control and AgRPp53 KO mice fed a HFD. Representative immunofluorescence showing
GFP expression in the ARC (j); body weight change (k); cumulative food intake (l); fat mass (m); representative infrared thermal images and temperature
of the BAT (n); representative BAT histology pictures (hematoxylin-eosin) (o); BAT protein levels of UCP1 in control mice (p) and JNK1 KO mice (q) and
representative WAT histology pictures (hematoxylin-eosin) (r) of control and JNK1 KO mice after 6 days of the injection of Ad-GFP and Ad-DNp53RK in
the ARC. α-tubulin was used to normalize protein levels. Dividing lines indicate spliced bands from the same gel. Values are mean ±4–10 animals per group.
*P < 0.05; **P < 0.01
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Discussion
The interest in p53 has classically been focused in its anti-
tumorigenic action, but has expanded into the field of metabolism
by the findings that cancer cells must maintain an accelerated
metabolic rate to cope with the energetic requirements of high
replication. In keeping with this, over the last few years, a large set
of data indicates that p53 plays an important metabolic role12,15,
with some of the evidence as follows: p53 has been shown to
modulate the activity of several key metabolic tissues, including
the WAT, where it is induced in obese, leptin-deficient mice21,
and where p53 upregulation led to insulin resistance20. p53 is also
present in liver, where it modulates lipid metabolism and is
increased in mouse models of fatty liver disease29. In BAT, the
role of p53 is still unclear but it is suggested to mediate BAT
thermogenic activity23,24,51. In contrast to the insight of p53
action in peripheral tissues, the metabolic role of p53 in the
hypothalamus remains almost completely unknown.
Consistent with a key role for p53 in metabolic regulation, our
pharmacological and genetic approaches here establish hypotha-
lamic p53 as a relevant player in the maintenance of energy
homeostasis. Deletion of p53 in AgRP neurons caused a dramatic
obese phenotype characterized by increased adiposity, slight
hyperphagia, and reduced energy expenditure in a setting of
nutrient excess. Importantly, these p53-related alterations in
energy balance were found to be nuclei-specific, since they were
only observed when p53 was manipulated in AgRP neurons and
not when it was ablated in the other main neuronal population of
the ARC, namely, POMC neurons or in SF1 neurons in the VMH.
The phenotype obtained following deletion of p53 in AgRP
neurons was difficult to predict since acute genetic ablation of
AgRP in adult animals leads to anorexia, whereas its neonatal
depletion reduces food intake and alters inter-organ commu-
nication, redirecting peripheral nutrient utilization toward
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Fig. 8 Genetic activation of p53 in the ARC ameliorates diet-induced obesity. Representative immunofluorescence images showing GFP expression in the
ARC (a); protein levels of acetyl-p53, phosphorylated p53, and in the mediobasal hypothalamus (b); body weight change (c); cumulative food intake
(d); fat mass and non-fat mass (e–f); energy expenditure (EE) (g); locomotor activity (LA) (h); respiratory quotient (RQ) (i); representative infrared
thermal images and temperature of the BAT area (j); representative BAT histology pictures (hematoxylin-eosin) (k); immunostaining of UCP1 in BAT
(l); representative WAT histology pictures (hematoxylin-eosin) (m); representative liver histology pictures (hematoxylin-eosin, upper and oil-red O
staining, lower) (n); and protein levels of GRP78, IRE1, pPERK, ATF6α, CHOP, MKK4, MKK7, pJNK, and JNK in the mediobasal hypothalamus (o) of DIO
mice after 7 days of the injection of Ad-GFP and Ad-p53 in the ARC. β-actin was used to normalize protein levels. Dividing lines indicate spliced bands from
the same gel. Values are mean ± SEM of 4–8 animals per group. *P < 0.05; **P < 0.01; ***P < 0.001
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hyperinsulinemia on regular chow, but reduced body weight gain
and paradoxical improves glucose tolerance on HFD54. In this
regard, our AgRPp53 KO mice show a similar phenotype, which
indicates that p53 plays a key role in some, but not all, the
functions of AgRP neurons, something that is consistent with the
fact that p53 is not expressed in 100% of AgRP neurons. Inter-
estingly, genetic ablation of p53 in AgRP neurons did not change
the electrical activity of these neurons. While we performed an
unbiased sampling of the GFP-labeled AgRP neurons, the reason
for this might be the heterogeneity of AgRP neurons and the
existence of different neuronal subsets. For instance, there is a
considerable differential gene expression among AgRP neurons
after food deprivation55. Alternatively, FACS sorting and single-
cell RNA sequencing showed that 69% of AgRP neurons express
p53. Therefore, it might be possible that some of the recorded
neurons would not be affected in our animal model, masking
potential effects of p53 on AgRP electrical activity.
Different intracellular processes within AgRP neurons have
been demonstrated to control energy homeostasis, including
autophagy56, mitochondrial dynamics57, or inflammation36.
Hypothalamic ER stress has also emerged as a relevant factor in
the development of obesity34–39,58. In the current study, we found
that genetic inhibition of p53 activity in the ARC, and more
specifically its deletion in AgRP neurons, increased the hypo-
thalamic expression of ER stress markers, while overexpression of
p53 in the ARC attenuated DIO-induced hypothalamic ER stress.
In this regard, the recovery of p53 in AgRP neurons of AgRPp53
KO mice fed a HFD, reversed their obese phenotype, and sti-
mulated BAT thermogenesis. Moreover, our results are also in
agreement with an in vitro study demonstrating that loss of p53
function activates the IRE1α/XBP1 pathway to enhance protein
folding, suggesting that defects in the p53 complex represents a
new mechanism for ER function modulation59,60. Furthermore,
we found that obese AgRPp53 KO mice centrally treated with
TUDCA showed a reduction in food intake, body weight, and
adiposity. These results are consistent with previous reports
indicating that reversal of central ER stress with chemical cha-
perones is able to decrease food intake and adiposity34,36,38,43.
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Fig. 9 Genetic recovery of p53 in AgRP neurons decreases body weight gain. Representative immunofluorescence images showing the colocalization of
GFP (green) and AgRP (red) in the ARC, as well as the colocalization of GFP (green) and DAPI (blue) (a); body weight change (b); cumulative food intake
(c); fat mass and non-fat mass (d–e); representative WAT histology pictures (hematoxylin-eosin) (f); representative infrared thermal images and
temperature of the BAT area (g); representative BAT histology pictures (hematoxylin-eosin) (h); and BAT UCP1 immunostaining (i) of AgRPp53 KO mice
injected with AAV-DIO-hSyn-EGFP or AAV-DIO-hSyn-EGFP-p53 in the ARC. Values are mean ± SEM of 5–8 animals per group. *P < 0.05; **P < 0.01;
***P < 0.001
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Despite the fact that lack of p53 in AgRP neurons activates
hypothalamic ER stress, this effect does not seem to be the pri-
mary cause leading to energy imbalance, as 3 weeks of HFD in
AgRPp53 KO did not cause differences in body weight or
expression of ER stress markers in comparison to their control
littermates. This indicates that hypothalamic ER stress is likely a
consequence rather than the cause of the obese phenotype. In
contrast, we found that phosphorylated levels of JNK in the
hypothalamus were increased in AgRPp53 KO mice before they
developed obesity. Protein levels of MKK7, one of the upstream
kinases responsible of JNK phosphorylation, also displayed sig-
nificant elevation in the mediobasal hypothalamus of AgRPp53
KO mice before body weight was increased. JNK in AgRP neu-
rons is known to play an important role in the control of energy
balance; for instance, JNK3 deficiency was associated with
enhanced excitatory signaling by AgRP neurons in HFD-fed
obese mice61, and in line with our results genetic activation of
JNK1 signaling in AgRP neurons is sufficient to induce weight
gain and adiposity in mice62. Consistently, the pharmacological
inhibition of central JNK reversed the obese phenotype of
AgRPp53 KO mice, by decreasing body weight and increasing
BAT thermogenic activity. Moreover, p53 inhibition caused
energy imbalance in WT but not in JNK1-deficient mice.
Although the regulation of JNK activity by p53 has been studied
largely in the context of apoptosis and autophagy63,64, our find-
ings indicate that the hypothalamic p53/JNK pathway is also
relevant in the control of energy balance. In this regard, it is
important to note that obese AgRPp53 KO mice did not show
changes in markers of inflammation, apoptosis or senescence in
the hypothalamus, suggesting that the higher susceptibility to
DIO is independent of those factors. Indeed, we cannot discard
that hypothalamic p53 might have a role in apoptosis and
senescence at higher ages, since our experiments were performed
in relatively young mice that did not present any sign of tumor.
Finally, since the ARC is the primary hypothalamic area
reached by circulating signals, we assessed the possibility that p53
in AgRP neurons might also act as a mediator of ghrelin actions.
In this sense, we have previously shown that p53 is essential for
the orexigenic and adipogenic action of ghrelin28,65. Taking into
account that AgRP neurons are the main target for ghrelin49,50,66,
we found that, contrary to control mice, ghrelin was unable to
induce food intake and body weight gain in AgRPp53 KO mice.
Thus, p53 specifically located in AgRP neurons is essential for the
orexigenic and adipogenic actions of ghrelin. Moreover, acyl-
ghrelin levels were significantly increased in AgRPp53 KO3 mice,
suggesting that these mice are overcompensating ghrelin resis-
tance by increasing the circulating levels of active ghrelin.
Overall, our findings point to a fundamental and specific role
for p53 in AgRP neurons in the regulation of energy homeostasis.
The high susceptibility to obesity of AgRPp53 KO mice is cor-
related with a decreased energy expenditure and BAT thermo-
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Fig. 10 Central ghrelin fails to stimulate food intake and body weight in AgRPp53 KO mice. Body weight change (a); cumulative food intake (b); ARC mRNA
expression of NPY and AgRP (c); representative WAT histology pictures (hematoxylin-eosin) (d); mRNA expression of FAS, ACC, and LPL in the WAT of
control (e) and AgRPp53 KO mice (f) and serum acyl-ghrelin levels in control and AgRPp53 KO mice treated i.c.v. with saline or ghrelin. Values are mean ±
SEM of 6–9 animals per group. *P < 0.05; **P < 0.01
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mediated by hypothalamic JNK activity. Finally, the genetic
overexpression of hypothalamic p53 in the ARC or specifically in
AgRP neurons of obese mice decreased body weight and
increased BAT activity. These results support that beyond its
actions as a tumor suppressor, hypothalamic p53 is critical to
maintain energy balance.
Methods
Animal care. 8–10-week-old (250–300 g) male Sprague Dawley rats and C57/BL6
WT mice were housed under conditions of controlled temperature (23 °C) and
illumination (12-h light/12-h dark cycle). They were allowed ad libitum access to
water and standard chow (Harlan Research Laboratories) or HFD (60% Kcal fat;
Research Diets) (starting at 5 weeks of age). Care of all animals was within insti-
tutional animal care committee guidelines, and all procedures were reviewed and
approved by the Ethics Committee of the University of Santiago de Compostela, in
accordance with European Union normative for the use of experimental animals.
Generation of p53-conditional knock out mice. We used the cre-lox system to
delete p53 in AgRP, POMC, or SF-1 neurons. p53loxP/loxP mice were purchased
from The Jackson Laboratory (B6; 129S4 Trp53tm5Tyj/J). To investigate the role of
AgRP, POMC, or SF-1-expressing neurons, we inactivated the p53 gene specifically
in each of these neurons by crossing p53loxP/loxP mice with mice expressing Cre
recombinase under control of the AgRP, POMC, or SF-1 promoter67. Cre-
mediated recombination was visualized by the use of a reporter mouse strain with
the Cre inducible tdTomato-reporter mouse B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTo-
mato)Hze/J (Jackson Laboratories)30.
Physiological measurements. Body weights and food intake were determined
weekly. Whole-body composition was measured using NMR imaging (Whole Body
Composition Analyzer; EchoMRI, Houston, TX). Animals were monitored in a
custom 12-cage indirect calorimetry, food intake, and locomotor activity mon-
itoring system (TSE LabMaster, TSE Systems, Germany) as previously
described68,69. Mice were acclimated for 48 h to the test chambers and then were
monitored for an additional 48 h. Data collected from the last 48 h was used to
calculate all parameters for which results are reported. Heat production was
visualized using a high-resolution infrared camera (FLIRSystems) as previously
described68. Plasma Glucose tolerance tests and insulin sensitivity tests were per-
formed on 4–6 h food-deprived mice. D-glucose (2 g/kg) and insulin (0.7 IU/kg)
were injected intraperitoneally (i.p.) and blood glucose determined at the indicated
time points. Blood glucose was measured using a Glucometer (Arkray) from the tail
vein. Circulating T4 levels were measured by Total Thyroxine (T4) ELISA kit from
Crystal Chem (Ref. 80983) according to manufacturer instructions. Animals were
killed by decapitation and were not food-deprived before sampling. Tissues were
removed rapidly, frozen immediately on dry ice, and kept at −80 °C until analysis.
Stereotaxic microinjection of adenoviral expression vectors. Ad libitum fed
rats were anesthetized by an i.p. injection of ketamine (100 mg/kg body weight)/
xylazine (15 mg/kg body weight). Adenoviral vectors encoding a double-mutant
kinase dead p53 regulating kinase (DNTp53RK) acting as a dominant negative (the
TP53RK clone was then mutated at g217a and a218t to E73M) that block p53
activation and function (Ad-DNp53RK) (1.0 × 1010 PFU/mL) (SL115889; Signa-
Gen Laboratories, Gaithersburg, MD) or GFP controls (1.0 × 1010 PFU/mL)
(SL100708) were injected bilaterally into the ARC AP: −2.85 mm, L: ±0.3 mm, and
V: −10.2 mm, with a 25-gauge needle (Hamilton) or into VMH AP: −2.4/3.2 mm,
L: ±0.6 mm, and V: −10.1 mm, as previously reported70–72.
C57BL/6 mice were fed with HFD for 12 consecutive weeks (starting at 5 weeks
of age). Mice were anesthetized by an i.p. injection of ketamine/xylazine cocktail
(ketamine 15 mg/kg BW/xylazine 3 mg/kg BW) and placed in a stereotaxic frame
(Kopf Instruments). Adenoviral vectors containing the tumor protein p53 (1.0 ×
1010 PFU/mL) (SL109638) or Ad-GFP (1.0 × 1010 PFU/mL) (SL100708; Signagen
Laboratories) were injected in the ARC. The ARC was targeted bilaterally using a
32-gauge needle connected to a 1-ml syringe (Neuro-Syringe, Hamilton) and
adenoviral vectors were delivered at a rate of 0.1 μl/min for 7 min (0.7 μl/injection
site) according to the following coordinates: −1.5 mm posterior to the bregma,
±0.2 mm lateral to midline, and −6 mm below the surface of the skull as previously
reported.
Ad libitum fed C57BL/6 mice or JNK knock out mice were anesthetized and
placed in a stereotaxic frame (Kopf Instruments). Ad-DNp53RK or GFP controls
were injected bilaterally into the ARC. Correct ARC adenoviral delivery was
assessed by immunofluorescence analysis. After the procedure, the incision was
closed with sutures, and mice were placed in a heated cage until they recovered
from anesthesia. Body weight and food intake were measured daily for 5
consecutive days after the surgery.
To rescue the expression of p53 specifically in AgRP neurons, we injected in the
ARC AAV-DIO-hSyn-EGFP or AAV-DIO-hSyn-p53-EGFP (2.48 × 1013 PFU/mL)
or p53 (3.23 × 1013 PFU/mL) (Vector Builder) under cell-specific cre promoters.
AgRPp53 KO and AgRP-Cre mice fed a HFD for 10 weeks before to viral injections
were anesthetized and placed in a stereotaxic frame (Kopf Instruments). Body
weight and food intake were recorded until 4 weeks after the surgery. Specific
overexpression of p53 in AgRP neurons was evaluated by immunohistochemistry.
i.c.v. treatments. i.c.v. surgery was carried out on 16-week-old male AgRPp53 KO
mice, in littermate controls, and in 8-week-old rats. Mice were anaesthetized with a
ketamine/xylazine cocktail (ketamine 15 mg/kg BW/xylazine 3 mg/kg BW) and i.c.
v. cannulae were implanted stereotaxically (David Kopf Instruments, Tujunga,
CA), in the lateral ventricle73. The coordinates used were −0.6 mm posterior to
bregma, ±1.2 mm lateral from midline, and −2.0 mm ventral from the brain sur-
face for mice. For rats we used the following coordinates: −0.9 mm posterior to
bregma, ±1.5 mm lateral from midline, and −3.5 mm ventral from the brain sur-
face, as described previously38,70,72,74. After surgery, the animals were singly
housed and given at least 4 days to recover. AgRPp53 KO mice were infused with
2 µl of either vehicle (saline), or TUDCA (2.5 µg/µl) (Calbiochem) for 7 consecutive
days (once a day, 1 h before lights off), as described previously38. In a separate
experiment AgRPp53 KOP mice were infused with 2 µl of either vehicle (DMSO) or
JNK inhibitor (SP-600125; 1.5 µg/mice)44 for 6 consecutive days (once a day, 1 h
after the light on). Food intake and body weights were recorded daily. After the
pharmacological treatment or vehicle injection, mice were either culled to dissect
the hypothalamus studies. Finally AgRPp53 KO mice were infused with 2 µl of
either vehicle (saline), or ghrelin (2.5 µg/µl) (Bachem) for 2 consecutive days (once
a day, 1 h after lights on) food intake and body weights were recorded daily and at
2, 4, and 6 h after the first injection.
Rats were anesthetized by an i.p. injection of ketamine/xylacine cocktail mixture
(ketamine 100 mg/kg BW/xylazine 15 mg/kg BW). Brain infusion cannulae were
stereotaxically placed into the lateral ventricle or directly into the ARC or VMH
(Plastic One, Roanoke, VA, USA). Rats were anesthetized and cannulate to an
osmotic minipump (model 2001 Alzet Osmotic Pumps; DURECT, CA) as
previously described73. The minipump was inserted in subcutaneous pocket on the
dorsal surface. The incision was closed with sutures, and rats were kept warm until
full recovery. Rats were infused with either vehicle (saline) or p53 agonist
(adriamycin 1 μg/rat/day) along the time of the experiments. To test the
contribution of the SNS, a specific antagonist of the β3-adrenergic receptor,
SR59230A (3 mg/kg/day; Tocris Bioscience Bristol), was administrated
subcutaneously at the beginning and at the end of the light cycle during the
treatment with adriamycin24,71.
Electrophysiology. Perforated patch clamp recordings were performed on AgRP
neurons in brain slices from male AgRP-Cre and AgRPp53 KO mice fed a HFD for
10 weeks and injected in the mediobasal hypothalamus with AAV-DIO-hSyn-
EGFP that expressed GFP specifically in AgRP neurons. Experiments were carried
out essentially as described previously75. Briefly, AgRP neurons were identified
according to their anatomical location in the ARC and reporter expression. Brain
slices were continuously superfused with carbogenated artificial cerebrospinal fluid
(aCSF) (~31 °C) at a flow rate of ~2 ml/min (recording chamber volume: ~2 ml).
aCSF contained (in mM): 125 NaCl, 2.5 KCl, 2 MgCl2, 2 CaCl2, 1.2 NaH2PO4, 21
NaHCO3, 10 HEPES, 5 glucose, adjusted to pH 7.2 with NaOH, resulting in an
osmolarity of ~310 mOsm. Recordings were performed with pipette solution
containing 1% biocytin (Sigma) and (in mM): 128 K-gluconate, 10 KCl, 10 HEPES,
2 MgCl2, and adjusted to pH 7.3 with KOH. Initially, the patch pipette was tip filled
with internal solution and back filled with 0.02% tetraethylrhodamine-dextran
(D3308, Invitrogen, Eugene, OR, USA) and Amphotericin B-containing internal
solution (∼200 μg ml−1; A4888, Sigma) to achieve perforated patch recordings76,77.
Amphotericin B was dissolved in DMSO (D8418, Sigma) as described previsously78
and was added to the modified pipette solution shortly before use. To block
GABAergic and glutamatergic synaptic input the aCSF contained 10−4 M picro-
toxin (P1675; Sigma-Aldrich), 5 × 10−5 M D-AP5 (A5282; Sigma-Aldrich), and
10−5 M CNQX (C127; Sigma-Aldrich). During the perforation process access
resistance (Ra) was constantly monitored and experiments were started after Ra had
reached steady state (~15–20 min) and the action potential amplitude was stable.
To confirm the integrity of the perforated patch recording, Ra was monitored over
the course of the experiment. A change to the whole-cell configuration was also
indicated by Dextran-Fluorescein fluorescence in the cell body.
Neuron labeling. After the electrophysiological experiments, perforated-patch
recordings were converted to the whole-cell configuration and biocytin was allowed
to diffuse into the cell for at least 1 min. Biocytin-streptavidin labeling combined
with GFP immunohistochemistry was performed as previously described75.
Data analysis. Data analysis was performed with Spike2 (CED), Igor Pro 6
(Wavemetrics), and Graphpad Prism (version 5.0c; Graphpad Software Inc.). Data
are given as mean ± standard error. To determine differences in means between
genotypes, unpaired t-tests were performed. A significance level of 0.05 was
accepted for all tests. N-values and p-values are reported as exact numbers above
the bar graphs.
Excitability: To analyze excitability, i.e., evoked action potential firing, a series of
depolarizing current pulses (5–25 pA in 5 pA increments; 5 s duration) were
injected. For each current pulse the number of action potentials was determined.
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SFA: To determine SFA ratios 5 s depolarizing stimuli were applied from a
holding potential of ~−70 mV with initial instantaneous AP frequencies between
30 and 35 Hz. Instantaneous frequencies were plotted over the 5 s time course and
fit to a mono-exponential decay equation with Y0 set to the initial instantaneous
frequency: Y= (Y0−Plateau) · exp(−K·X)+ Plateau, where Plateau is the
asymptotic frequency, K is the inverse time constant, and T is the time.
Western blot analysis. Western blot was performed as previously described72,74.
Briefly, animals fed ad libitum were sacrificed and protein lysates from ARC
(20 μg) and MBH (20 μg) were subjected to sodium dodecyl sulfate–polyacrylamide
gel electrophoresis, electrotransferred on a polyvinylidene difluoride membrane,
and probed with different antibodies (Supplementary Table 1). For protein
detection we used horseradish peroxidase-conjugated secondary antibodies (Dako
Denmark, Glostrup, Denmark) and chemiluminescence (Pierce ECL Western
Blotting Substrate; Thermo Scientific, Waltham, MA). Then, the membranes were
exposed to radiograph film (Super RX, Fuji Medical X-Ray Film; Fujifilm, Tokyo,
Japan) and developed with developer and fixing liquids (AGFA, Mortsel, Belgium)
under appropriate dark room conditions. The protein levels were normalized to β-
actin or α-tubulin for each sample. Uncropped blots are shown in Supplementary
Fig. 16.
Immunofluorescence. Rats and mice brains were fixed by perfusion followed by
immersion (12 h) in 10% buffered formalin for 24 h. The brain pieces were cut
50 μm thick using a Vibratome® Series 1000. Detection of GFP, fluorescein iso-
cthiocyanate, TOMATO immunofluorescence, and double labeling were performed
as previously reported71 using a mouse anti-p53 antibody (Cell Signaling Tech-
nology 2524).
Real-time PCR. RNA was extracted using Trizol® reagent (Invitrogen) according to
the manufacturer’s instructions. 2 µg of total RNA were used for each RT reaction,
and cDNA synthesis was performed using the SuperScript™ First-Strand Synthesis
System (Invitrogen) and random primers (Supplementary Table 2) as previously
described24.
Hematoxylin/eosin staining and immunohistochemistry. WAT, BAT, and liver
samples were fixed in 10% formalin buffer for 24 h, and then dehydrated and
embedded in paraffin by a standard procedure. Sections of 3 μm were prepared
with a microtome and stained using a standard Hematoxylin/Eosin Alcoholic
(BioOptica) procedure according to the manufacturer's instructions73. Alternative
sections of paraffin were used for immunohistochemistry detection of UCP-1.
Immunohistochemistry was performed as described24,79 using a rabbit anti-UCP-1
(1:2000; Abcam; Cambridge, UK). UCP-1-positive cells were counted by using
Frida Software (the Johns Hopkins University; Baltimore, MD, USA). Up to 10
animals per experimental group were used and 3 pictures per each image sections
were analyzed.
AgRP immunohistochemistry and fiber densitity analysis. Mice were trans-
cardially perfused (4% paraformaldehyde) . Brains were cryoprotected, frozen in
smashed dry ice, and subsequently sectioned using a freezing microtome. Selected
30 mm sections (one of every four sections) were blocked with 2% chicken serum
in KPBS+ 0.4% Triton X-100 and incubated with rabbit anti-AGRP antibody
(1:500; Phoenix Pharmaceuticals), rabbit anti-GFAP (Dako; Agilent), or rabbit
anti-iba1 (ionized calcium-binding adapter molecule 1; Synaptic Systems)80 in
blocking solution for 72 h at 4 °C. As secondary antibody, a chicken anti-rabbit
Alexa Fluor 488 (1:300; Life Technologies) in KPBS+ 0.4% Triton X-100 was used
(2 h at room temperature). For quantification, representative sections through the
PVH (bregma between −0.59 and −1.23 mm) and ARC (bregma between −1.43
and −1.91 mm) of each animal were acquired using a Leica DMI 4000B confocal
microscope equipped with a 20× objective (numerical aperture 0.70). Ten image
stacks with 1 µm distance interval throughout the PVH and ARC of each animal
were taken. AgRP fiber density analysis was then performed using ImageJ Launcher
and based on previously published reports81. Briefly, each single image was
binarized to compensate for differences in fluorescence intensity, specified in a
random 200 × 200 µm region and skeletonized, so that each fiber segment was
1 pixel thick. The integrated intensity was then measured for each image. The total
density value was obtained by the sum of all image planes analyzed.
Data analysis and statistics. Data are expressed as mean ± SEM. mRNA and
protein data were expressed in relation (%) to control (vehicle-treated) rats. Error
bars represent SEM. Statistical significance was determined by Student’s t-test when
two groups were compared or ANOVA and post hoc two-tailed Bonferroni test
when more than two groups were compared. P < 0.05 was considered significant.
Data availability. All data generated or analyzed during this study are included in
this published article (and its Supplementary Information files) or from the authors
upon reasonable request.
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